CRDN

Views & Analysis

Tunnah’s musings: Rare diseases hold key to future of drug d...

The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.

Views & Analysis

Rethinking rare diseases: treat the whole patient

CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.

News

Veraxa says delayed US listing is back on track

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks